CC
The Chemours Company
$12.87
Stable Earnings Power
40%
P/Adj-EPS × Normalized Multiple
Moderate
·
Conviction
Overvalued
Trading 20.2% above fair value
You pay
$12.87
Bear
$8.57
Fair
$10.71
Bull
$12.85
Bear
$8.57
-33.4%
$0.71 × 12x P/E
Fair
$10.71
-16.8%
$0.71 × 15x P/E
Bull
$12.85
-0.1%
$0.71 × 18x P/E
Adjust Assumptions
15.0x
0.71$
Key Value Driver
Normalized P/E multiple (15x base case)
Implied Market Multiple
18.0x
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above.
Average Target (20 analysts)
$18.89
Divergence from AlphaVal
43%
Summary
Applying a 15x P/E to adjusted EPS of $0.71, the base-case value is $10.71 per share.
Warnings
Wall Street's average price target is $18.89 (from 20 analysts). Our estimate is 43% below the consensus -- consider that gap carefully.
This stock is 55% below its 52-week high, with weak or declining earnings. That combination often signals real trouble, even though the valuation below is based on other fundamentals.
Key Risks
- Growth DCF inappropriate — terminal value assumptions dominate
- EV/EBITDA misleading for regulated businesses where capex is mandated
- Regulatory risk is a fat tail not visible in normal multiples